Abstract--The fibrinolysis induced by intraperitoneal injection of adrenaline in the rat was inhibited by prior intraperitoneal injection of very low doses of &alpha;-adrenergic blocking agents. For example, 5 &mu;g/kg of phenoxybenzamine or 10 &mu;g/kg of phentol amine was sufficient to prevent almost completely the fibrinolysis induced by 1 mg/kg of adrenaline. These a-blockers also inhibited the fibrinolysis induced by serotonin and bisobrin, but a much higher dosage was required. Phenoxybenzamine did not inhibit the adrenaline-induced fibrinolysis when the drug was injected after the in jection of adrenaline.
ceptor, since noradrenaline and isoproterenol were both equally effective in enhancing fibrinolysis. In man, prior administration of propranolol did not affect exercise-induced fibrinolysis (7) , while the 9-blocker only partially inhibited the fibrinolysis induced by intravenous adrenaline infusion (8) . Kral et al. (9) reported a complete inhibition of the adrenaline-induced fibrinolysis in man by a 9-adrenergic blocker, alprenolol. a Adrenergic blockers have not been shown to exert any effect on the adrenaline-induced fibrinolysis in man (8, 10) .
We undertook to investigate this problem using the rat as an experimental animal and a series of a and Q-adrenergic blocking agents as tools for differentiating the adrenergic receptor of the adrenaline-induced fibrinolysis. This fibrinolytic system of rat stimulated by an i.p. injection of large doses of adrenaline has been used by Schor et al. for screening synthetic fibrinolytic compounds (11, 12). In our experiments, the fibrinolytic action This work was presented in part at the 45th Annual Meeting of the Japanese Pharmacological Society in April 1972 in Sendai and was published in abstract form in Japan J. Pharmacol. 22, suppl. 1: 120 (1972) of adrenaline in the rat was found to be inhibited by extremely low doses of a-adrenergic blockers.
MATERIALS AND METHODS Animals
Male Sprague-Dawley rats (150-220 g) were fed commercial laboratory chow for more than a week before the start of experiments. Drugs DL-phenylephrine HCI, phenoxybenzamine HC1, dibenamine HCI , i_-noradrenaline HCI and serotonin creatinine sulfate were purchased from Tokyo Chemical Industry Co., Ltd. Phosphate-citrate buffer: 23.9 g Na2HPO4.12H20 was dissolved in 900 ml of dis tilled water, and to this were added solutions of 3.02 g KH2PO4 in 250 ml and 0.25 g tri sodium citrate in 100 nil. The final pH of the solution was 7.4. The buffer was heat-ste rilized and stored at 4'C.
Thrombin solution: Thrombin (500 National Institutes of Health units) was dis solved in 100 ml sterile physiological saline and stored below -20'C until used. All pi pettes and test tubes coming into contact with diluted blood or blood clot were made of polyethylene.
Fibrinolysis assay
The general method for measurement of fibrinolytic activity was based on Fearnley's dilute blood clot lysis method (13, 14). Drugs were dissolved in saline and injected either i.p. or i.v. via the tail vein. After various intervals of time, blood was withdrawn into a plastic syringe from the abdominal aorta with the animal under ether anesthesia. One ml of the blood was immediately diluted 20 times with ice cold phosphate-citrate buffer. The blood was mixed in an ice bath, and was kept cold until used. Four ml of the dilute blood was then clotted with thrombin (5 NIH-units) in a test tube. The tube was placed in an ice bath for one hr and then transferred to an incubator maintained at 37'C. After 3 hr incubation, the remaining clot was separated from the supernatant by discarding the latter and boiled in 10 ml of 0.1 N NaOH for 5 min to convert the hemoglobin to alkaline hematin. The concentration of the latter was determined spectrophotometrically (540 nm). To calculate the percentage of clot lysis, we used the following equation. Fibrinolysis induced by adrenaline, noradrenaline and phenylephrine Although either i.v. or s.c. injection of adrenaline (5 min after 0.05-30 sag/kg, i.v. ; 10 min after 1 mg/kg, s.c.) or forced exercise (swimming in water) did not cause any increase in fibrinolysis in the rat, large i.p. doses of the catecholamine brought about dose-depen dent increases in the fibrinolytic activity as reported by Schor et at. (Fig. 1) . The fibri nolytic activity reached a maximum at about 10 min after the injection and returned to the normal level in 30 min (Fig. 2) . Noradrenaline and phenylephrine also showed this pro perty, but the maximum fibrinolysis by phenylephrine occurred 5 min after injection (Fig. 2) .
Behavior changes caused by the i.p. injection of large doses of adrenaline were weak tachycardia, slight dilation of the pupils, limb weakness and low pelvic position. Effects of cr-blockers on adrenaline-induced fibrinolysis We first examined effects of ce-blockers (phenoxybenzamine, dibenamine and phentol amine) on the adrenaline-induced fibrinolysis by injecting the blockers i.p. 10 or 20 min before the injection of adrenaline. As shown in Fig. 3A , the fibrinolysis induced by adre naline (1 mg/kg, i.p.) was found to be completely inhibited by a previous injection of phe noxybenzamine (51eg/kg). From the dose-inhibition curve in Fig. 3A , the dose (ID50) of phenoxybenzamine that would give a half-maximal inhibition was estimated to be 1.4
Fio. 3. Effects of a-adrenergic blockers and propranolol on adrenaline-induced fibri nolysis. Rats were injected i.p. with phenoxybenzamine HCl (A) and dibena mine HC1 (B) 20 min before, and with phentolamine mesylate (C) and propra nolol HCl (D) 10 min before, the i.p. injection of adrenaline HC1 (1 mg/kg) and bled 10 min after the injection of adrenaline. Each point represents mean r SE of 5 rats. Untreated control rats (0) were given saline twice instead of drug solutions, and adrenaline-treated control rats (C') were given saline prior to the adrenaline injection.
FIG. 4. Effect of i.v. administered phenoxybenzamine on adrenaline-induced fibrino lysis. Rats were injected i.v. with phenoxybenzamine HCI 10 min before the i.p. injection of adrenaline HCI (1 mg/kg), and were bled 10 min after the injec tion of adrenaline. Each point represents mean±SE of 5 rats. Untreated control rats (40) were given saline twice instead of drug solutions, and adre naline-treated control rats (Q) were given saline prior to the adrenaline injection.
,ug/kg. Intravenous injection of phenoxybenzamine was also effective in preventing the adrenaline-induced fibrinolysis, but much higher doses were required to produce signifi cant inhibitions, the 1D50 in this case being 301eg/kg (Fig. 4) . The inhibitory effects of dibenamine and phentolamine on the adrenaline-induced fibrinolysis were less marked than that of phenoxybenzamine, but inhibitory doses were far less than the dose of adre naline ( Fig. 3B and 3C ). When phenoxybenzamine was injected 5 min after the injection of adrenaline, no inhibitory effect was observed even at a dose of 100 ,ag/kg. The a blockers added in vitro into the assay system showed no inhibitory effect at a concentration of 50 ,peg/ml. These inhibitors (100-200,ug/4 ml diluted blood) were also without effect on the action of urokinase (10 NIH-units/4 ml diluted blood) in vitro.
One might assume that the a-blockers may elicit an intrinsic inhibitor of the fibrinoly tic system in the rat. This possibility was tested by examining fibrinolysis of mixed blood samples from a-blocker-treated rats and from adrenaline-treated rats. The blood sam ples withdrawn from rats injected with phenoxybenzamine (10 mg/kg, i.p.) or phentolamine (15 mg/kg, i.p.) 20 min after the injection did not inhibit the fibrinolysis of blood samples taken from rats injected with adrenaline (1 mg/kg, i.p., blood withdrawn 10 min after the injection) when both were mixed in vitro. From these experiments, it was concluded that the inhibition of adrenaline-induced fibrinolysis by the a-blockers is caused neither by direct inhibition of the fibrinolytic system nor by production of endogenous inhibitors of fibrinolysis in the cy-blocker-treated animal. 
Effects of a-blockers on adrenaline-induced fibrinolysis
Effects of the j-blockers propranolol, DC1, pronethalol and practolol on the adre naline-induced fibrinolysis are shown in Fig. 3D and Fig. 5 . The pre-treatment of rats with DCI, pronethalol or practolol did not inhibit the adrenaline-induced fibrinolysis even at a dose of 10 mg/kg, but rather stimulated it slightly (Fig. 5) . Propranolol, on the other hand, exerted an inhibitory effect at a dose of 3 mg/kg, and the ID50 for propranolol was 1.9 mg/kg as shown in Fig. 3D . This value was much higher than those for the a-blockers. reported that the synthetic compound bisobrin, when properly administered, possesses a fibrinolytic activity without serious pharmacological side effects (11, 12, 17). We there fore studied the effect of phenoxybenzamine on the bisobrin-induced fibrinolysis in rats (Fig. 6C) . The bisobrin-induced fibrinolysis was also inhibited by phenoxybenzamine (1 mg/kg, i.v.) and its sensitivity (ID50=320,ug/kg) to phenoxybenzamine was between that of the adrenaline and serotonin-induced fibrinolyses.
Constriction of mesenteric arteries by adrenergic amines and its inhibition by phenoxy benzamine The fact that the i.p. route is more effective than the i.v. route for both adrenaline and phenoxybenzamine suggests that the site of action may be blood vessels in the peritoneal cavity. Therefore, the rat peritoneum was exposed and effects of the above compounds on the mesenteric arteries and veins were observed under a low-magnification microscope. When one drop of an adrenaline solution (200 ,ug/ml saline) was allowed to fall onto the peritoneum, the mesenteric arteries which came into contact with the solution constricted instantaneously, while the veins apparently remained unaffected. If the adrenaline solu tion was dropped over an area where the tissues had previously been moistened with one drop of phenoxybenzarnine solution (20 ppg/ml saline), the constriction of the arteries was no longer observed. Similar phenomena were observed when the adrenaline solution was replaced by solutions of noradrenaline and phenylephrine. DISCUSSION The rat is not considered a suitable experimental animal to use as a substitute for humans in studies of fibrinolysis, since the level of antifibrinolytic activity in rat plasma is much higher than that in human plasma (18). Adrenaline-induced fibrinolysis as measured by the dilute whole blood lysis test was observed only when rats were treated with high i.p. doses of adrenaline (12). These high, but sublethal, doses would probably be enough to elicit the plasminogen activator or other afibrinolytic activators in amounts sufficent to overcome the high level of antifibrinolytic activity. Although it is not known to what extent this fibrinolysis induced by adrenaline in the rat shares common aspects with phy siological fibrinolysis in man, its inhibition by extremely low doses of a-adrenergic blockers deserves attention. To our knowledge, in no case has an inhibition of adrenaline action by a-adrenergic blockers been observed at such low a-blocker/adrenaline dose ratios as used in the present study. Furthermore, this inhibition seems to have resutled from a specific blockade of the adrenergic receptor, because the phenylephrine or noradrenaline induced fibrinolysis was also prevented by low doses of phenoxybenzamine, while a much higher dosage was required to inhibit the fibrinolyses induced by other types of fibrinolytic agents, serotonin and bisobrin. Inhibition of plasmin or urokinase activity by the a adrenergic blockers or a release of antiplasmin from the animal tissue after phenoxy benzamine injection has been ruled out. The lack of an inhibitory effect by a-blockers in adrenaline-induced stimulation of fibrinolysis in man (8, 10) indicates that the elevation of fibrinolytic activity by a constant infusion of adrenaline involves different mechanisms.
Among the four Q-adrenergic blockers tested, only propranolol showed an inhibi tion at relatively high doses, while the other three were rather stimulatory. This slight activation of fibrinolysis by the (3-blockers suggests that the j3-adrenergic action of adre naline may have been suppressed so as to let the antagonistic ct-adrenergic property exert its full action on the target tissue (e.g. blood vessels). In man, propranolol partially (8) and alprenolol completely (9) inhibited the increase in fibrinolytic activity brought about by adrenaline infusion.
Holemans (6) has suggested various mechanisms by which plasminogen activator could be released from vessel walls into the circulation by the action of vasoactive substances on the vessel walls. The most likely site of action of i.p. administered adrenaline would then be the mesenteric blood vessels which would receive direct, sustaining actions of the injected adrenaline, since the i.p. route was the only effective route of injection for the fibrinolytic action of adrenaline. The fact that a much smaller dosage is required for a similar degree of inhibition by phenoxybenzamine when it is administered i.p. rather than i.v. also indicates that the site of the fibrinolytic action of adrenaline is in the pertioneal cavity. The inhibition by phenoxybenzamine of the adrenaline-induced constriction of mesenteric arteries correlates with the inhibition of the adrenaline-induced fibrinolysis by the cr-adre nergic blocker. Sato and Nagao in this laboratory showed that an i.p. injection of adre naline (I mg/kg) did not produce the typical rise in the systemic blood pressure in the rat at least for 30 min, whereas a prior injection of phenoxybenzamine (10 1 g/kg, i.p.) by the same route induced the pressor response just as observed when adrenaline was given in travenously (unpublished observation). The intraperitoneal adrenaline may not enter the circulation due to the constriction of the peritoneal blood vessels which in turn would induce local hemostasis, while with phenoxybenzamine, an antagonist of the vasocon striction by adrenaline, adrenaline would enter the circulation freely through the walls of the peritoneal blood vessels and exert its systemic pressor action. The plasmin acti vator is probably released from the constricted areas of the peritoneal blood vessels into the circulation, and phenoxybenzamine may have a strong affinity towards the receptor of the peritoneal blood vessels upon which adrenaline exerts its vasoconstrictor action.
